Oppenheimer: Time To Buy ConforMIS, Two Catalysts Are Coming Next Year Read more

By Monica Gerson

In a report published Monday, Oppenheimer analyst Steven Lichtman initiated coverage of ConforMIS Inc CFMS 4.79% with an Outperform rating and a price target of $26.

ConforMIS is a commercial-stage orthopedics company currently focusing on implants used in total and partial knee arthroplasty procedures.

Analyst Steven Lichtman pointed out, “CFMS’s unique iFit technology provides custom implants designed to match the individual anatomy of a patient undergoing total knee replacement surgery.”

The company’s proprietary software technology offers several benefits including faster recovery and better comfort for the patient. Its aim is to reduce hospital costs by reducing required instrumentation, improving operating room turnover and reducing the readmission charges.


Related Articles

Back to top button